医学
米诺地尔
皮肤病科
不利影响
安慰剂
科克伦图书馆
敏感皮肤
腺苷
梅德林
随机对照试验
内科学
替代医学
病理
政治学
法学
作者
Blythe N. Ke,Juan Paolo David S. Villena,Ma. Lorna F. Frez
出处
期刊:Acta medica Philippina
日期:2020-06-23
卷期号:54 (3)
标识
DOI:10.47895/amp.v54i3.1678
摘要
Background. Androgenetic alopecia (AGA), also known as pattern hair loss, is the most common type of hair loss in men and women. Due to very limited therapeutic options, search for other effective and safe drugs is necessary.
Objectives. This review aims to evaluate the efficacy and safety of a potential treatment option, topical adenosine, for AGA in male and female adults.
Methods. A search of databases (Cochrane Library, Pubmed Medline, and others) was performed with no time limitations placed. We included human interventional studies published in English involving the use of topical adenosine for AGA in healthy adult males and females. Risk bias assessment was performed using the Cochrane Collaboration criteria.
Results. All four trials in this review, with a total of 260 participants, used 0.75% topical adenosine lotion twice a day for a period of 6-12 months. Comparators were placebo, topical niacinamide, and topical minoxidil. Evaluated parameters include improvement in baldness grading as assessed by dermatologists and investigators, improvement and satisfaction as assessed by participants, anagen growth, thick/thin/vellus hair ratio, and hair density. Two trials found significant improvement with thick hair ratio (>60 or >80 μm) with the use of topical adenosine while two trials showed higher overall participant satisfaction with topical adenosine. Few to no adverse effects were reported with its use.
Conclusion. This is the first systematic review involving topical adenosine for AGA. Topical adenosine may be effective in increasing thick hair ratio and improving the self-perception of hair growth. With minimal to no adverse effects, it may serve as an adjunct or alternative to present treatment options. However, more studies are needed to strengthen these findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI